Table 3.
Main findings of the included studies about 18F-DCFPyL PET/CT in BRPCa patients.
| References | Overall DR on a per patient-based analysis | DR in patients with PSA < 0.5 ng/ml | DR in patients with PSA ≥ 0.5 ng/ml | DR in patients with PSA between 0.5 and 1 ng/ml | DR in patients with PSA between 1 and 2 ng/ml | DR in patients with PSA ≥ 2 ng/ml | Local recurrence | Regional lymph node recurrence | Distant lymph node recurrence | Bone | Organ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Markowski et al. (31) | 82/108 (75.9%) |
26/46 (56.5%) |
56/62 (90.3%) |
NA | NA | NA | NA | NA | NA | NA | NA |
| Hong et al. (32) | 61/72 (84.7%) |
4/8 (50%) |
57/64 (89.0%) |
9/13 (69%) |
5/5 (100%) |
43/46 (93.5%) |
22/72 (31%) |
34/72 (48%) |
20/72 (28%) |
33/72 (46%) |
11/72 (16%) |
| Wei et al. (33) | 69/79 (87.0%) |
NA | NA | NA | NA | NA | 54/79 (68%) |
21/79 (27%) |
14/79 (18%) |
NA | NA |
| Jansen et al. (34) | 16/24 (66.7%) |
NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Rowe et al. (35) | 21/31 (67.7%) |
NA | NA | NA | NA | NA | 8/31 (25.8%) |
14/31 (45.1%) |
2/31 (6.5%) |
2/31 (6.5%) |
0/31 (0%) |
| Mena et al. (36) | 70/90 (77.8%) |
10/21 (47.6%) |
60/69 (90%) |
5/10 (50%) |
8/9 (88.9%) |
47/50 (94%) |
29/90 (32.2%) |
39/90 (43.3%) |
17/90 (18.8%) |
9/90 (10.0%) |
5/90 (5.5%) |
| Rousseau et al. (37) | 110/130 (84.6%) |
3/5 (60%) |
107/125 (85.6%) |
18/23 (78.3%) |
18/25 (72%) |
71/77 (92.2%) |
35/130 (26.9%) |
57/130 (43.8%) |
32/130 (24.6%) |
26/130 (20.0%) |
3/130 (2.3%) |
| Wondergem et al. (38) | 214/248 (86.3%) |
17/29 (59%) |
197/217 (90.8%) |
20/29 (69%) |
35/41 (85%) |
142/149 (95%) |
92/248 (37.1%) |
136/248 (54%) |
49/248 (19.8%) |
73/248 (29.4%) |
12/248 (4.8%) |
| Dietlein et al. (39) | 46/62 (74.2%) |
1/8 (12.5%) |
45/54 (83.3%) |
NA | NA | NA | NA | NA | NA | NA | NA |
| Pooled values (95% confidence interval) |
80.2% (75.6–84.7%) |
47.2% (32.6–61.8%) |
88.8% (86.2–91.3%) |
70.3% (60.2–80.5%) |
82.9% (74.5–91.3%) |
94.3% (91.8–96.9%) |
36.6% (33.1–40.2%) |
45.8% (42.1–49.6%) |
19.3% (16.2–22.3%) |
20.5% (17.3–23.6%) |
4.2% (2.6–6.0%) |
NA, not available; DR, detection rate; PSA, prostate-specific antigen; BRPCa, biochemically recurrent prostate cancer; 18F-DCFPyL, 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; PET/CT, positron emission tomography/computed tomography.